Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 131

1.

A randomized, controlled trial of raltegravir intensification in antiretroviral-treated, HIV-infected patients with a suboptimal CD4+ T cell response.

Hatano H, Hayes TL, Dahl V, Sinclair E, Lee TH, Hoh R, Lampiris H, Hunt PW, Palmer S, McCune JM, Martin JN, Busch MP, Shacklett BL, Deeks SG.

J Infect Dis. 2011 Apr 1;203(7):960-8. doi: 10.1093/infdis/jiq138.

2.

Treatment intensification with raltegravir in subjects with sustained HIV-1 viraemia suppression: a randomized 48-week study.

Llibre JM, Buzón MJ, Massanella M, Esteve A, Dahl V, Puertas MC, Domingo P, Gatell JM, Larrouse M, Gutierrez M, Palmer S, Stevenson M, Blanco J, Martinez-Picado J, Clotet B.

Antivir Ther. 2012;17(2):355-64. doi: 10.3851/IMP1917. Epub 2011 Sep 28.

PMID:
22290239
3.

The effect of intensification with raltegravir on the HIV-1 reservoir of latently infected memory CD4 T cells in suppressed patients.

Vallejo A, Gutierrez C, Hernandez-Novoa B, Diaz L, Madrid N, Abad-Fernandez M, Dronda F, Perez-Elias MJ, Zamora J, Muñoz E, Muñoz-Fernandez MA, Moreno S.

AIDS. 2012 Sep 24;26(15):1885-94.

PMID:
22992577
4.

Raltegravir intensification shows differing effects on CD8 and CD4 T cells in HIV-infected HAART-suppressed individuals with poor CD4 T-cell recovery.

Massanella M, Negredo E, Puig J, Puertas MC, Buzón MJ, Pérez-Álvarez N, Carrillo J, Clotet B, Martínez-Picado J, Blanco J.

AIDS. 2012 Nov 28;26(18):2285-93. doi: 10.1097/QAD.0b013e328359f20f.

PMID:
23018435
5.

Effect of raltegravir intensification on HIV proviral DNA in the blood and gut mucosa of men on long-term therapy: a randomized controlled trial.

Chege D, Kovacs C, la Porte C, Ostrowski M, Raboud J, Su D, Kandel G, Brunetta J, Kim CJ, Sheth PM, Kaul R, Loutfy MR.

AIDS. 2012 Jan 14;26(2):167-74. doi: 10.1097/QAD.0b013e32834e8955.

PMID:
22089379
6.

Early but limited effects of raltegravir intensification on CD4 T cell reconstitution in HIV-infected patients with an immunodiscordant response to antiretroviral therapy.

Negredo E, Massanella M, Puertas MC, Buzón MJ, Puig J, Pérez-Alvárez N, Pérez-Santiago J, Bonjoch A, Moltó J, Jou A, Echeverría P, Llibre JM, Martínez-Picado J, Clotet B, Blanco J.

J Antimicrob Chemother. 2013 Oct;68(10):2358-62. doi: 10.1093/jac/dkt183. Epub 2013 May 14.

8.

No effect of raltegravir intensification on viral replication markers in the blood of HIV-1-infected patients receiving antiretroviral therapy.

Gandhi RT, Coombs RW, Chan ES, Bosch RJ, Zheng L, Margolis DM, Read S, Kallungal B, Chang M, Goecker EA, Wiegand A, Kearney M, Jacobson JM, D'Aquila R, Lederman MM, Mellors JW, Eron JJ; AIDS Clinical Trials Group (ACTG) A5244 Team.

J Acquir Immune Defic Syndr. 2012 Mar 1;59(3):229-35. doi: 10.1097/QAI.0b013e31823fd1f2.

9.

The effect of raltegravir intensification on low-level residual viremia in HIV-infected patients on antiretroviral therapy: a randomized controlled trial.

Gandhi RT, Zheng L, Bosch RJ, Chan ES, Margolis DM, Read S, Kallungal B, Palmer S, Medvik K, Lederman MM, Alatrakchi N, Jacobson JM, Wiegand A, Kearney M, Coffin JM, Mellors JW, Eron JJ; AIDS Clinical Trials Group A5244 team.

PLoS Med. 2010 Aug 10;7(8). pii: e1000321. doi: 10.1371/journal.pmed.1000321.

10.

Raltegravir treatment intensification does not alter cerebrospinal fluid HIV-1 infection or immunoactivation in subjects on suppressive therapy.

Dahl V, Lee E, Peterson J, Spudich SS, Leppla I, Sinclair E, Fuchs D, Palmer S, Price RW.

J Infect Dis. 2011 Dec 15;204(12):1936-45. doi: 10.1093/infdis/jir667. Epub 2011 Oct 21.

11.

Dynamics of CD8 T-cell activation after discontinuation of HIV treatment intensification.

Massanella M, Esteve A, Buzón MJ, Llibre JM, Puertas MC, Gatell JM, Domingo P, Stevenson M, Clotet B, Martinez-Picado J, Blanco J; IntegRal Collaborative Group.

J Acquir Immune Defic Syndr. 2013 Jun 1;63(2):152-60. doi: 10.1097/QAI.0b013e318289439a.

PMID:
23392458
12.

Short-course raltegravir intensification does not reduce persistent low-level viremia in patients with HIV-1 suppression during receipt of combination antiretroviral therapy.

McMahon D, Jones J, Wiegand A, Gange SJ, Kearney M, Palmer S, McNulty S, Metcalf JA, Acosta E, Rehm C, Coffin JM, Mellors JW, Maldarelli F.

Clin Infect Dis. 2010 Mar 15;50(6):912-9. doi: 10.1086/650749.

13.

CD4+ T cell recovery beyond the first year of complete suppression of viral replication during highly active antiretroviral therapy is not influenced by CD8+ T cell activation.

Benito JM, Lopez M, Lozano S, Ballesteros C, Capa L, Martinez P, Gonzalez-Lahoz J, Soriano V.

J Infect Dis. 2005 Dec 15;192(12):2142-6.

PMID:
16288380
14.

The role of extended-release niacin on immune activation and neurocognition in HIV-infected patients treated with antiretroviral therapy - CTN PT006: study protocol for a randomized controlled trial.

Lebouché B, Jenabian MA, Singer J, Graziani GM, Engler K, Trottier B, Thomas R, Brouillette MJ, Routy JP.

Trials. 2014 Oct 7;15:390. doi: 10.1186/1745-6215-15-390.

15.

Nucleoside-free boosted double PI regimen: significant CD4+ T-cell recovery in patients with poor immunologic response despite virologic suppression.

Lehmann C, Jung N, Hofmann A, Cornely OA, Wyen C, Fätkenheuer G, Hartmann P.

Curr HIV Res. 2008 Nov;6(6):555-9.

PMID:
18991621
16.

Combination antiretroviral therapy with raltegravir leads to rapid immunologic reconstitution in treatment-naive patients with chronic HIV infection.

Pallikkuth S, Fischl MA, Pahwa S.

J Infect Dis. 2013 Nov 15;208(10):1613-23. doi: 10.1093/infdis/jit387. Epub 2013 Aug 6.

17.

Intensification of antiretroviral therapy with raltegravir or addition of hyperimmune bovine colostrum in HIV-infected patients with suboptimal CD4+ T-cell response: a randomized controlled trial.

Byakwaga H, Kelly M, Purcell DF, French MA, Amin J, Lewin SR, Haskelberg H, Kelleher AD, Garsia R, Boyd MA, Cooper DA, Emery S; CORAL Study Group.

J Infect Dis. 2011 Nov 15;204(10):1532-40. doi: 10.1093/infdis/jir559. Epub 2011 Sep 19.

PMID:
21930607
18.

HIV-1-specific cytolytic T-lymphocyte activity correlates with lower viral load, higher CD4 count, and CD8+CD38-DR- phenotype: comparison of statistical methods for measurement.

Lubaki NM, Shepherd ME, Brookmeyer RS, Hon H, Quinn TC, Kashamuka M, Johnson M, Gottle R, Devers J, Lederman HM, Bollinger RC.

J Acquir Immune Defic Syndr. 1999 Sep 1;22(1):19-30.

PMID:
10534143
19.

Differential upregulation of CD38 on different T-cell subsets may influence the ability to reconstitute CD4+ T cells under successful highly active antiretroviral therapy.

Benito JM, López M, Lozano S, Ballesteros C, Martinez P, González-Lahoz J, Soriano V.

J Acquir Immune Defic Syndr. 2005 Apr 1;38(4):373-81.

PMID:
15764953
20.

Efficacy and safety of raltegravir for treatment of HIV for 5 years in the BENCHMRK studies: final results of two randomised, placebo-controlled trials.

Eron JJ, Cooper DA, Steigbigel RT, Clotet B, Gatell JM, Kumar PN, Rockstroh JK, Schechter M, Markowitz M, Yeni P, Loutfy MR, Lazzarin A, Lennox JL, Strohmaier KM, Wan H, Barnard RJ, Nguyen BY, Teppler H; BENCHMRK Study Teams.

Lancet Infect Dis. 2013 Jul;13(7):587-96. doi: 10.1016/S1473-3099(13)70093-8. Epub 2013 May 7.

PMID:
23664333

Supplemental Content

Support Center